*Dr. Fauci's pushing an apparently worthless drug, to upstage
hydroxychloroquine, and *
*make **way for that vaccine without which we won't be allowed out into the
world (if any).*

*MCM*

8,265 views|May 26, 2020,02:08pm EDT
Remdesivir Revealed

https://www.forbes.com/sites/williamhaseltine/2020/05/26/remdesivir-revealed-what-the-finally-released-data-tells-us/
[image: image.jpeg]


<https://www.forbes.com/sites/williamhaseltine/>
William A. Haseltine <https://www.forbes.com/sites/williamhaseltine/>
Contributor
Healthcare <https://www.forbes.com/healthcare>

   -
   -
   -

[image: Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc.,
Reports Positive Data Coming From Trials]

FOSTER CITY, CALIFORNIA - APRIL 29: A sign is posted in front of the Gilead
Sciences headquarters on ... [+]
 GETTY IMAGES

The full data from the remdesivir trial by the National Institutes of
Health (NIH) has finally been released
<https://www.nejm.org/doi/full/10.1056/NEJMoa2007764>, weeks after preliminary
results
<https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19>
were
shared via press release. Those early results generated a great deal of
hype and a world wide stampede for the drug. But the release of the full
data tells a different story.

The conclusion of the NIH study, published in *The New England Journal of
Medicine, *states:

*“These preliminary findings support the use of remdesivir for patients who
are hospitalized with Covid-19 and require supplemental oxygen therapy.
However, given high mortality despite the use of remdesivir, it is clear
that treatment with an antiviral drug alone is not likely to be sufficient.
Future strategies should evaluate antiviral agents in combination with
other therapeutic approaches or combinations of antiviral agents to
continue to improve patient outcomes in Covid-19.”*

There are a few problems this paragraph highlights.

First, by opening with a reference to the data “preliminary findings” the
authors are acknowledging the fact that this is not a definitive study. How
could it be with such scant data? Ideally, this NIH trial and other
remdesivir trials would continue to gather evidence to support the
findings. But the NIH controversially ended
<https://www.statnews.com/2020/05/11/inside-the-nihs-controversial-decision-to-stop-its-big-remdesivir-study/>
their
large trial of the drug and Gilead has suspended smaller trials
<https://www.biospace.com/article/gilead-shutters-covid-19-trial-in-china-stocks-drop-3-percent-/>.
More study of the drug will still be conducted through the WHO Solidarity
Trial
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments>
and
the Inserm DisCoVeRy Trial <https://clinicaltrials.gov/ct2/show/NCT04315948>,
so there is at least a glimmer of hope that we will eventually have robust
and transparent data that shows the true impact of the drug on viral load.

*Click on the link for the rest.*

-- 
If you appreciate News From Underground, please consider making a donation — 
either a one-time gift or a monthly subscription: 
http://markcrispinmiller.com/support/
Thank you for your support.

Ways to unsubscribe:
1) send a blank email to [email protected]
PLEASE NOTE: you must unsubscribe using the SAME email with which you subscribed

2) go to http://groups.google.com/group/newsfromunderground and click on the 
"Unsubscribe or change membership" link in the yellow bar at the top of the 
page, then click the "Unsubscribe" button on the next page.

For more News From Underground, visit http://markcrispinmiller.com
--- 
You received this message because you are subscribed to the Google Groups "News 
From Underground" group.
To unsubscribe from this group and stop receiving emails from it, send an email 
to [email protected].
To view this discussion on the web visit 
https://groups.google.com/d/msgid/newsfromunderground/CAGxB6W_t1DcbT_6bdegn152Fd%3D1o%2BfC%3DFzr_%3D4VfA7fF%2BG%3DAUA%40mail.gmail.com.

Reply via email to